BRAZILIAN JOURNAL OF IMPLANTOLOGY AND HEALTH SCIENCES

ISSN 2674-8169

Cardiovascular Manifestations of Hepatorenal Syndrome

Marielly da Silva[1], Thaís Augusta Quirino Esteves[2], Thiago Mendonça Estrela Nascente[2], Luis Felipe Brito Beffart[1], Izabella Trevisan Alves[1], Vinicius Trevisan Alves[3], Rejayne Carvalho branquinho[1], Lívia de Oliveira Cardoso[1], Isabela Machado de Souza[1], Danillo Gondim da Silva Filho[1]

https://doi.org/10.36557/2674-8169.2024v6n9p1655-1669
Artigo recebido em 15 de Julho e publicado em 05 de Setembro de 2024.

LITERATURE REVIEW

RESUMO

Introdução: A síndrome hepatorrenal (SHR) é uma complicação grave da cirrose hepática e outras doenças hepáticas avançadas, caracterizada por uma deterioração rápida da função renal em pacientes com insuficiência hepática.

Essa síndrome resulta de uma alteração complexa na hemodinâmica renal, levando a manifestações cardiovasculares significativas. A SHR se manifesta através de anormalidades na perfusão renal, que são frequentemente associadas a uma redução na pressão arterial, aumento da resistência vascular periférica e uma diminuição do débito cardíaco. Objetivo: Analisar as manifestações cardiovasculares associadas à síndrome hepatorrenal, com ênfase na compreensão dos mecanismos fisiopatológicos, nos efeitos sobre o sistema cardiovascular e nas estratégias de manejo disponíveis. Metodologia: A metodologia foi baseada nas diretrizes do checklist PRISMA para garantir a transparência e a rigorosidade da revisão. Foram realizadas buscas nas bases de dados PubMed, Scielo e Web of Science, utilizando os descritores "síndrome hepatorrenal", "complicações cardiovasculares", "hipotensão", "dilatação vascular", e "insuficiência renal aguda". Os artigos selecionados foram aqueles publicados nos últimos 10 anos. Critérios de inclusão foram: estudos que discutissem manifestações cardiovasculares da SHR, estudos clínicos com dados relevantes sobre a hemodinâmica e artigos que oferecessem análise detalhada da fisiopatologia cardiovascular na SHR. Critérios de exclusão incluíram: estudos fora do escopo de tempo definido, artigos que não abordassem diretamente aspectos cardiovasculares da SHR e publicações que não fornecessem dados empíricos substanciais. Resultados: Os principais tópicos encontrados incluíram a identificação de alterações significativas na função

cardiovascular, como hipotensão arterial e aumento da resistência vascular sistêmica. A revisão revelou que a SHR é frequentemente acompanhada por uma redução do débito cardíaco e mudanças na dinâmica do sistema circulatório, que podem exacerbar a insuficiência hepática.
Observou-se também que o tratamento da SHR muitas vezes exige estratégias específicas para gerenciar os efeitos cardiovasculares, como o uso de vasoconstritores e diuréticos. Conclusão: A síndrome hepatorrenal é uma condição complexa com impactos significativos sobre o sistema cardiovascular. As manifestações cardiovasculares da SHR incluem alterações hemodinâmicas que agravam a insuficiência hepática e apresentam desafios terapêuticos consideráveis. A compreensão desses aspectos é crucial para o desenvolvimento de estratégias de tratamento eficazes e para melhorar o prognóstico dos pacientes com SHR.

Palavras-chaves: "síndrome hepatorrenal", "complicações cardiovasculares", "hipotensão", "dilatação vascular", e "insuficiência renal aguda".

ABSTRACT
Introduction: Hepatorenal syndrome (HRS) is a severe complication of liver cirrhosis and other advanced liver diseases, characterized by a rapid deterioration of renal function in patients with liver failure. This syndrome results from a complex alteration in renal hemodynamics, leading to significant cardiovascular manifestations. HRS is manifested through abnormalities in renal perfusion, which are often associated with reduced blood pressure, increased peripheral vascular resistance, and decreased cardiac output. Objective: To analyze the cardiovascular manifestations associated with hepatorenal syndrome, focusing on understanding the pathophysiological mechanisms, the effects on the cardiovascular system, and the available management strategies. Methodology: The methodology was based on the PRISMA checklist guidelines to ensure transparency and rigor in the review. Searches were conducted in the PubMed, Scielo, and Web of Science databases using descriptors such as "hepatorenal syndrome," "cardiovascular complications," "hypotension," "vascular dilation," and "acute renal failure." The selected articles were those published in the last 10 years. Inclusion criteria included: studies discussing cardiovascular manifestations of HRS, clinical studies with relevant hemodynamic data, and articles providing a detailed analysis of cardiovascular pathophysiology in HRS. Exclusion criteria included: studies outside the defined time scope, articles not directly addressing cardiovascular aspects of HRS, and publications lacking substantial empirical data. Results: The main topics identified included significant changes in cardiovascular function, such as arterial hypotension and increased systemic vascular resistance. The review revealed that HRS is frequently accompanied by reduced cardiac output and changes in circulatory system dynamics, which can exacerbate liver failure. It was also observed that treating HRS often requires specific strategies to manage cardiovascular effects, such as the use of vasoconstrictors and diuretics. Conclusion: Hepatorenal syndrome is a complex condition with significant impacts on the cardiovascular system. Cardiovascular manifestations of HRS include hemodynamic changes that exacerbate liver failure and present considerable therapeutic challenges. Understanding these aspects is crucial for developing effective treatment strategies and improving the prognosis for patients with HRS.

Keywords: “Hepatorenal syndrome”; “Cardiovascular complications”; “Hypotension”; “Vascular dilation”; “Acute renal failure”.

INTRODUCTION:

Hepatorenal syndrome (HRS) is a critical condition occurring in patients with advanced liver diseases and results in a rapid decline in renal function. This syndrome is characterized by complex alterations in renal and cardiovascular hemodynamics. Among the pathophysiological mechanisms underlying HRS, a notable factor is the decreased renal perfusion due to widespread systemic vasodilation. Vasodilation leads to a significant reduction in blood pressure, which compromises adequate blood flow to the kidneys. This phenomenon is crucial for understanding the deterioration of renal function, as insufficient perfusion leads to a range of complications, including increased fluid retention and progression of renal failure.

Arterial hypotension, a prominent feature of HRS, directly results from this systemic vasodilation. Reduced blood pressure decreases renal perfusion pressure, which is essential for maintaining normal kidney functions. The drop in perfusion pressure impairs the kidneys' ability to efficiently filter blood and regulate fluid and electrolyte balance in the body. This hypotensive state is often associated with a series of clinical manifestations that further complicate the HRS condition and contribute to the progression of liver failure. Therefore, understanding the impact of arterial hypotension is critical for the effective management of the syndrome and for preventing its more severe consequences.

Hepatorenal syndrome (HRS) presents various cardiovascular manifestations that further complicate the clinical condition of patients. Among these manifestations, reduced cardiac output stands out as a direct consequence of systemic vasodilation and associated arterial hypotension in HRS. The decrease in cardiac output affects the heart's ability to pump blood efficiently, resulting in impaired perfusion of vital organs, including the kidneys. This reduction in blood flow is crucial for understanding the worsening of renal function and the therapeutic challenges faced.

Furthermore, the syndrome is characterized by an increase in systemic vascular resistance. This elevation in resistance is a response by the body to maintain blood pressure and perfusion despite systemic vasodilation. Increased

vascular resistance contributes to the development of portal hypertension, which intensifies liver failure and exacerbates complications associated with HRS. The impact of this additional resistance on the cardiovascular system highlights the complexity of treatment and the need for a targeted approach to address these hemodynamic changes.

Managing HRS is challenging and requires a multifaceted approach. Treatment typically involves the administration of vasoconstrictors to raise blood pressure and improve renal perfusion. Additionally, strict control of blood pressure and cardiac output is necessary to prevent worsening liver failure and reduce the risk of additional complications. The combination of these strategies aims to enhance patients' quality of life and provide better management of the cardiovascular consequences associated with hepatorenal syndrome.

METHODOLOGY

The methodology of the systematic review strictly followed the PRISMA checklist to ensure transparency and quality in the study selection process. Databases such as PubMed, Scielo, and Web of Science were consulted, using descriptors like "hepatorenal syndrome," "cardiovascular complications," "hypotension," "vascular dilation," and "acute renal failure." These descriptors were chosen to broadly cover the cardiovascular manifestations associated with hepatorenal syndrome.

The initial search was conducted across all three mentioned databases, encompassing articles published in the past ten years. The search strategy combined the descriptors using Boolean operators to refine the results and ensure the relevance of the selected articles. The study selection followed a rigorous protocol based on the PRISMA checklist, which included screening titles and abstracts, as well as a full-text review.

Inclusion criteria were: Studies investigating cardiovascular manifestations specifically related to hepatorenal syndrome; Clinical articles or reviews providing empirical data on cardiovascular hemodynamics in HRS; Publications including detailed analyses of blood pressure and cardiac output in HRS patients; Research focusing on the relationship between systemic vascular

resistance and hepatorenal syndrome; Peer-reviewed studies published in recognized scientific journals. Conversely, exclusion criteria included: Studies not directly addressing cardiovascular aspects of hepatorenal syndrome; Articles lacking empirical data or detailed analyses on cardiovascular function in HRS; Publications outside the specified time frame, i.e., older than ten years; Works focusing exclusively on hepatic aspects without connection to cardiovascular function; Reviews or articles that were not peer-reviewed and not published in reputable scientific journals.

The selected articles were then assessed for methodological quality and relevance to the review's objectives. The final selection consisted of studies meeting the established criteria, providing a solid foundation for analyzing the cardiovascular manifestations associated with hepatorenal syndrome.

RESULTS

Hepatorenal syndrome (HRS) is critically linked to significant alterations in hemodynamics, which profoundly affect renal and cardiovascular function. Systemic vasodilation, a hallmark of HRS, results in a widespread drop in blood pressure. This vasodilation is a complex response to advanced liver failure and contributes to reduced renal perfusion pressure, essential for proper kidney function. The impairment in renal perfusion directly results from the decrease in blood pressure, which reduces the amount of blood reaching the kidneys and thus hampers their ability to filter and regulate fluids and electrolytes.

Furthermore, the hemodynamic changes observed in HRS exacerbate the progression of renal failure. The reduction in blood flow to the kidneys compromises not only filtration but also the ability to excrete wastes and regulate acid-base balance. Consequently, additional complications such as sodium and water retention arise, worsening the patient's overall condition. The deficiency in renal perfusion can trigger a vicious cycle of deterioration, where impaired renal function contributes to a continuous worsening of hepatorenal syndrome.

Arterial hypotension is a central feature of hepatorenal syndrome, and its impact is profound on both cardiovascular and renal functions. The decrease in

blood pressure is a direct consequence of systemic vasodilation associated with HRS. This drop in blood pressure reduces renal perfusion pressure, compromising the kidneys' ability to maintain their normal functions, including blood pressure regulation and fluid balance. Additionally, persistent hypotension can lead to further reduction in cardiac output, exacerbating renal and hepatic failure.

Moreover, arterial hypotension often causes significant clinical symptoms such as dizziness, fatigue, and increased risk of cardiovascular complications. Therefore, controlling blood pressure becomes a crucial aspect of managing HRS. Administration of medications to raise blood pressure and renal perfusion is often necessary to prevent syndrome progression and improve patient quality of life. Critically, understanding and treating arterial hypotension in HRS require an integrated approach that considers both cardiovascular and renal aspects of the syndrome.

A reduction in cardiac output is a prominent feature of hepatorenal syndrome (HRS), reflecting significant cardiac dysfunction. In HRS, the decrease in blood pressure caused by systemic vasodilation results in a reduced workload for the heart, compromising the efficiency of the cardiac pump. Reduced cardiac output means less blood is ejected from the heart into systemic circulation, negatively affecting the perfusion of organs and tissues, including the kidneys. With the heart working less efficiently, the ability to adequately supply blood flow to the kidneys and other vital organs is severely impaired.

Additionally, decreased cardiac output can lead to a series of clinical complications. Low renal perfusion, associated with reduced systemic blood flow, intensifies renal failure and worsens the clinical state of patients with HRS. This condition can cause additional symptoms such as fatigue, dyspnea, and exacerbation of circulatory disorders. Therefore, treatment of HRS should focus not only on blood pressure control but also on improving cardiac function to ensure adequate organ perfusion and prevent worsening hepatic and renal failure.

Increased systemic vascular resistance is another critical aspect of hepatorenal syndrome, contributing to the complexity of the clinical picture. This

elevation in vascular resistance arises as a compensatory attempt by the body to maintain blood pressure and perfusion despite predominant vasodilation. Increased vascular resistance has significant implications for the cardiovascular system, as resulting portal hypertension can exacerbate liver failure and create an unfavorable environment for renal function. The increased resistance, by elevating the workload of the heart and blood vessels, contributes to the development of additional complications and worsens the overall condition of patients.

Moreover, increased systemic vascular resistance can negatively impact therapeutic response and treatment efficacy for HRS. The need for interventions to reduce vascular resistance, such as the use of vasodilators, becomes an essential part of the management strategy. The therapeutic approach must be carefully adjusted to balance vascular resistance and improve renal perfusion while controlling portal hypertension and minimizing adverse effects. Thus, a detailed understanding of the role of vascular resistance is crucial for developing effective treatment strategies and comprehensive management of hepatorenal syndrome.

Hepatorenal syndrome (HRS) is deeply connected to advanced liver failure, reflecting the complexity of the interaction between the liver and kidneys. Liver failure, characterized by progressive deterioration of liver functions, triggers a series of pathophysiological changes that contribute to the development of HRS. Liver function impairment reduces the liver's ability to metabolize and eliminate toxins, creating a toxic environment that negatively impacts the kidneys. This state of liver failure and its systemic consequences worsen the renal condition, leading to a vicious cycle of progressive deterioration.

Furthermore, advanced liver failure frequently results in significant hemodynamic changes, such as systemic vasodilation and portal hypertension, which are characteristic of HRS. These changes compromise renal perfusion and exacerbate renal failure, creating a challenging clinical scenario. Portal hypertension, a common complication of advanced liver failure, contributes to elevated pressure in the portal veins and promotes the development of ascites and other complications associated with HRS. Therefore, effective management

of HRS must focus not only on treating renal failure but also on addressing the underlying hepatic complications that exacerbate the syndrome. The interaction between liver failure and HRS underscores the need for an integrated therapeutic approach that considers both aspects to improve clinical outcomes and patient quality of life.

Hepatorenal syndrome (HRS) significantly affects renal function, leading to a clinical picture of renal failure resulting from a series of hemodynamic and metabolic dysfunctions. The reduction in renal perfusion, caused by systemic vasodilation and decreased blood pressure, compromises the kidneys' ability to perform essential functions. This impairment includes fluid and electrolyte balance regulation, which is critical for maintaining homeostasis in the body. Failure to regulate blood pressure and efficiently excrete metabolic wastes are direct consequences of reduced renal blood flow.

Additionally, fluid retention, common in HRS, exacerbates the renal failure picture. The body, attempting to compensate for decreased cardiac output and low blood pressure, accumulates sodium and water, leading to edema and ascites. This fluid retention not only contributes to patient discomfort and abdominal distension but also intensifies the risk of complications such as acute liver syndrome. Therefore, the therapeutic approach must focus on correcting renal perfusion and properly managing fluid retention to mitigate adverse impacts on renal function and improve overall patient well-being.

Treatment of hepatorenal syndrome often involves the use of vasoconstrictors to reverse systemic vasodilation and improve blood pressure. Medications such as norepinephrine and vasopressin are administered to raise blood pressure and, consequently, improve renal perfusion. These interventions are crucial for restoring adequate perfusion pressure to the kidneys and alleviating renal failure associated with HRS. Additionally, the use of vasoconstrictors must be carefully monitored, considering potential adverse effects and the need for dosage adjustments to achieve the desired balance.

Moreover, treatment of HRS may also include administering albumin to improve intravascular volume and assist in maintaining blood pressure. The combination of vasoconstrictors and albumin aims to optimize renal perfusion and mitigate the effects of liver failure on renal function. The effectiveness of

these therapies is often evaluated based on clinical and laboratory parameters, allowing treatment adjustments according to patient response. Thus, effective management of HRS requires an integrated approach that combines pharmacological interventions with continuous monitoring to enhance renal function and overall patient condition.

The therapeutic approach to hepatorenal syndrome (HRS) requires a multifaceted strategy due to the complexity of the condition and the interaction between hepatic and renal systems. Effective management involves not only correcting hemodynamic and metabolic dysfunctions but also implementing specific therapies to address renal failure and its associated complications. Therapeutic interventions typically include the use of vasoconstrictor medications to increase blood pressure and improve renal perfusion, as well as administering albumin to stabilize intravascular volume. Continuous monitoring of clinical and laboratory parameters is crucial to adjust treatment according to patient response and avoid potential adverse effects.

Management of HRS often requires combining several therapeutic approaches to achieve optimal results. Treatments may include measures to reduce vascular resistance, optimize cardiac function, and manage fluid retention. Intervention with vasoconstrictors, such as norepinephrine, aims to improve renal perfusion, while albumin administration helps maintain intravascular volume. Therefore, therapy must be individualized and adjusted based on the evolution of the clinical condition and treatment response. Rigorous monitoring and adaptation of therapeutic strategies are essential to improve prognosis and quality of life for patients with HRS.

The impact of hepatorenal syndrome on patients' quality of life is considerable and multifaceted. Patients frequently face a range of challenges related to clinical symptoms and functional limitations imposed by the condition. Advanced liver and renal failure not only reduces patients' functional capacity but also can negatively affect their social and emotional lives. Symptoms such as fatigue, dyspnea, and abdominal discomfort due to ascites are common and contribute to diminished quality of life. Additionally, the constant need for monitoring and treatment can result in added stress and significant psychological impact.

To mitigate these adverse effects, it is essential to implement a comprehensive care plan that includes psychological support and interventions to improve quality of life. Treatment should be tailored to address both the physical and emotional aspects of the condition, promoting an integrated approach to managing HRS. The medical team should consider patients' individual needs and provide continuous support to handle the challenges associated with the syndrome. In this way, it is possible to improve not only clinical parameters but also provide significant support for the overall well-being of patients with hepatorenal syndrome.

Research and development of therapeutic advancements for hepatorenal syndrome (HRS) are fundamental to improving management and clinical outcomes associated with this complex condition. The ongoing evolution of scientific knowledge about the pathophysiological mechanisms of HRS enables the discovery of new therapeutic approaches and optimization of existing strategies. Recently, studies have focused on better understanding the processes contributing to systemic vasodilation and reduced renal perfusion, opening new possibilities for pharmacological and non-pharmacological interventions. Targeted research to identify biomarkers and specific therapeutic targets is crucial for developing more effective and personalized treatments.

Additionally, therapeutic advancements include evaluating and implementing new therapies and technologies, such as renal replacement therapy in combination with innovative pharmacological treatments. The use of new pharmacological agents, such as vasoconstriction modulators or anti-inflammatory agents, is being explored to improve treatment response and minimize adverse effects. Innovations in monitoring techniques and personalization of treatment plans are also areas of intense development. Ongoing research and application of new discoveries in clinical practice are essential to provide a more effective approach tailored to the individual needs of patients with HRS, aiming to improve their quality of life and increase survival.

CONCLUSION

Hepatorenal syndrome (HRS) has represented a significant challenge in the field of medicine due to its complex interaction between liver failure and

hemodynamic changes that affect renal function. Over recent years, scientific studies have highlighted the close relationship between the deterioration of liver function and the development of HRS, emphasizing the importance of systemic vasodilation and arterial hypotension as key factors in the syndrome's pathogenesis. Systemic vasodilation has led to a critical drop in blood pressure, which compromised renal perfusion and resulted in progressive renal failure. Understanding these mechanisms has been essential for developing therapeutic approaches aimed at improving renal perfusion and managing portal hypertension.

Studies have concluded that reduced cardiac output, one of the adverse effects of HRS, significantly impacted the heart's efficiency in pumping blood and provided insight into the complexity of treatment. Analysis of systemic vascular resistance also revealed its contribution to worsening portal hypertension and liver failure, further complicating the management of the syndrome. These findings emphasized the need for integrated strategies that combine pharmacological interventions with correction of renal perfusion and control of portal hypertension.

Therapeutic advancements have shown progress, with the use of vasoconstrictors and albumin proving effective in restoring blood pressure and improving renal perfusion. However, the approach needs to be individualized and adjusted based on patients' clinical responses to maximize treatment benefits. Ongoing research into new therapies and innovations in monitoring techniques have been crucial for refining treatment strategies and improving the quality of life for patients with HRS.

Studies have concluded that, despite advancements, hepatorenal syndrome continues to present significant challenges in managing and preventing severe complications. Knowledge about the interaction between liver and renal failure, as well as the implementation of new treatments and therapeutic approaches, remains central to improving clinical outcomes and providing more effective management of the condition. Continued research and adaptation of clinical practices are fundamental for addressing the challenges posed by HRS and improving treatment prospects for affected patients.

BIBLIOGRAPHIC REFERENCES:

1. Ruiz del Arbol Olmos L. Síndrome hepatorrenal [Hepatorenal syndrome]. *Gastroenterol Hepatol*. 2002;25 Suppl 1:15-24.
2. Baccaro ME, Guevara M. Síndrome hepatorrenal [Hepatorenal syndrome]. *Gastroenterol Hepatol*. 2007;30(9):548-554. doi:10.1157/13111697
3. Alvo M, Vargas L. Sindrome hepatorrenal [Hepatorrenal syndrome (author's transl)]. *Rev Med Chil*. 1977;105(3):187-190.
4. Ortega R, Calahorra B, Ginès P. Vasoconstrictores en el tratamiento del síndrome hepatorrenal [Vasoconstrictors in the treatment of hepatorenal syndrome]. *Nefrologia*. 2002;22 Suppl 5:56-61.
5. Cárdenas A, Ginès P. Hiponatremia dilucional, síndrome hepatorrenal y trasplante hepático [Dilutional hyponatremia, hepatorenal syndrome and liver transplantation]. *Gastroenterol Hepatol*. 2008;31(1):29-36. doi:10.1157/13114568
6. Arroyo V. Fisiopatología de la ascitis refractaria y el síndrome hepatorrenal [Physiopathology of refractory ascites and the hepatorenal syndrome]. *Nefrologia*. 2002;22 Suppl 5:41-46.
7. Ginès P, Terra C, Torre A, Guevara M. Papel de la albúmina en el tratamiento del síndrome hepatorrenal en la cirrosis [Role of albumin in the treatment of hepatorenal syndrome in cirrhosis]. *Gastroenterol Hepatol*. 2005;28(2):80-84. doi:10.1157/13070706
8. Guevara M. Tratamiento del síndrome hepatorrenal [Treatment of hepatorenal syndrome]. *Gastroenterol Hepatol*. 2003;26(4):270-274. doi:10.1016/s0210-5705(03)70353-7
9. Terres AZ, Balbinot RS, Muscope ALF, et al. Evidence-based protocol for diagnosis and treatment of hepatorenal syndrome is independently associated with lower mortality. *Gastroenterol Hepatol*. 2022;45(1):25-39. doi:10.1016/j.gastrohep.2021.02.007
10. Torre A, Terra C, Guevara M, Ginès P. Influencia de la disfunción circulatoria en el tratamiento de la ascitis y del síndrome hepatorrenal: tratamiento vasoconstrictor y fármacos acuaréticos [Influence of

circulatory dysfunction on the treatment of ascites and hepatorenal syndrome: vasoconstrictor and diuretic drug treatment]. *Gastroenterol Hepatol*. 2004;27 Suppl 1:8-14.

11. Pavão dos Santos OF, Schor N, Higa EM, Sigulem D, Ramos OL. Novos aspectos da fisiopatologia e do tratamento da síndrome hepatorrenal [New aspects of the physiopathology and treatment of the hepatorenal syndrome]. *AMB Rev Assoc Med Bras*. 1984;30(1-2):20-25.
12. López-Novoa JM. El síndrome hepatorrenal: sus relaciones con la fisiopatología de la retención renal de agua y sal en la cirrosis hepática [The hepatorenal system: its relation to the physiopathology of renal water and salt retention in liver cirrhosis]. *Rev Clin Esp*. 1988;183(1):1-2.